The two companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH). The intended clinical trial will be a proof-of-concept study combining
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
NLS News
We asked the CEO of Herantis Pharma, Pekka Simula, about what is in their pipeline right now, about their strategy to reach market and about patient-driven innovation. Herantis Pharma was
The Board of Directors and Nomination Committee have proposed the appointment of Anna Ljung as the new CEO of Moberg Pharma, while current CEO Peter Wolpert will transition to a
Mene Pangalos, EVP and President, Research & Development BioPharmaceuticals at AstraZeneca, was awarded the Prix Galien Award Greece on April 11, 2019. The Prix Galien Award is presented to individuals
The two companies have announced an expansion of their partnership agreement (signed in 2017) to further include antibodies from LEO Pharma’s pipeline with the aim of achieving improvements in drug
The two companies have entered into a collaboration agreement to develop advanced end-to-end workflows for the preparation, characterization and monitoring of novel and complex biotherapeutics using liquid chromatography-mass spectrometry (LC-MS).
The company has resolved to carry out a directed new share issue of Class B Shares at a subscription price of SEK 10 per share. The directed new share issue
Don’t forget to subscribe to our magazine and read inspiring interviews, in-depth stories and articles about the Nordic life science industry’s progress and challenges. This issue is for example filled
The US patent and trademark office has issued a notice that they intend to grant additional patents to Oncopeptides AB in the US. These patents protect, inter alia, the freeze-dried
AstraZeneca and MSD have announced that the European Commission has approved Lynparza (olaparib) as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations (gBRCAm), and who have human epidermal growth
Lobsor Pharmaceuticals has reported that following Swedish MPA market approval in October 2018, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) has included Lecigon on Sweden’s list of reimbursed drugs.
The company has purchased a minority stake in the German company iRT Systems, in order to improve its quality assurance (QA) offering to clinics and hospitals. For the past six
The Board of the company has appointed Christoffer Lorenzen as the new CEO, replacing Peter Blom. Christoffer Lorenzen, born 1975, is currently an Executive Vice President and member of the
Together with LTS Lohmann Therapie-Systeme the company will start the first-ever clinical trial of microarray patches for the local intradermal treatment of psoriasis. The study will start in April 2019
Sponsored content
Cell and Gene Therapy Developers: This Is What Your Logistics Provider Must Do
In this article, John Coleman, Business Unit Director at ATMP logistics provider YSDS Life Science, explores the crucial role of logistics providers in ensuring the seamless transport of ATMPs in while adhering to the standards for an optimal vein-to-vein process.
JOB ALERTS
Read the latest issue of our magazine!
No 01 2024 // Many scientists state that we are entering the golden age of CNS disease treatment. Learn more about some of the most recent progress being made within the field, including Nordic advances. This issue’s profile is professor Mia Phillipson, co-founder of Ilya Pharma, co-director at SciLifeLab, a member of the Royal Swedish Academy of Sciences, and a scientist pioneering immunotherapies. We have a special report on the life science financial landscape, including VC predictions for 2024, an interview with Thomas Eldered, Flerie Invest, and a global outlook. This issue also includes a special focus on the skills shortages within cell and gene therapy manufacturing, startup advice and what it is like to work as a Bioprocess Engineer.
The latest research news from the Nordic region
Nordic Life Science
The latest clinical trials
Sign up to our newsletter